Trial Profile
A randomized, double-blind, placebo-controlled, dose comparison study of the efficacy and safety of lonidamine for the treatment of symptomatic benign prostatic hyperplasia
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Lonidamine (Primary)
- Indications Benign prostatic hyperplasia
- Focus Therapeutic Use
- Sponsors Threshold Pharmaceuticals
- 25 Aug 2006 Status change
- 30 Nov 2005 New trial record.